NEW YORK: Drugmaker Johnson & Johnson said on Wednesday it would take a non-cash impairment charge of about US$610 million in the first quarter over its decision to stop the development of a skin disease treatment.
The drug, bermekimab, is a human monoclonal antibody that was being tested for the treatment of chronic skin diseases atopic dermatitis and hidradenitis suppurativa.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
